Amgen Inc. (AMGN)
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.
Here's Why Amgen (AMGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Development Justin G.
Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
Amgen (AMGN) came out with quarterly earnings of $6.02 per share, beating the Zacks Consensus Estimate of $5.26 per share. This compares to earnings of $4.97 per share a year ago.
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
